NL-OMON55683已完成不适用
Pharmacokinetic evaluation and local tolerability of dry powder amikacin via the Cyclops® in patients with drug susceptible tuberculosis - Amika-01
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Age above 18 years
- •* Diagnosed with DSTB, either by culture or molecular testing
- •* Obtained written informed consent
排除标准
- •* Pregnancy or breast feeding
- •* Subjects with known or suspected (by spontaneous reporting or by active
- •questioning) renal, auditory, vestibular or neuromuscular dysfunction.
- •* History of adverse events on previous amikacin or other aminoglycoside use
- •(by spontaneous reporting nor by active questioning)
- •* Concurrent use of aminoglycosides, cyclosporin, cisplatin, amfotericin B,
- •cephalosporins, polymyxins and vancomycin
研究者
相似试验
进行中（未招募）
不适用
To evaluate the pharmakcokinetics, tolerability and short term safety of ciprofloxacin in neonates and infants with suspected (or proven) Gram Negative Infection Open Label pilot PK study - TINN Treat Infections in Neonates Program(TINN-PK) - TINN Treat Infections in Neonates Pharmocokinetics of CiprofloxaciEUCTR2010-019955-23-GBiverpool Women's NHS Foundation Trust
进行中（未招募）
1 期
Investigating the DopaFuse® Delivery System in Parkinson's Disease Patients. Assessing safety, effectiveness, how well it is tolerated, and how the drug is processed by the body.EUCTR2020-003372-41-ITSynAgile Corporation24
进行中（未招募）
1 期
Investigating the DopaFuse® Delivery System in Parkinson’s Disease Patients. Assessing safety, effectiveness, how well it is tolerated, and how the drug is processed by the body.Motor symptoms in Parkinson’s Disease.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003372-41-ESSynAgile Corporation24
已完成
1 期
Pharmacokinetics of lEvofloxacin FORmulations in children with MDR-TB exposure (PERFORM)TuberculosisPACTR202008476090763Stellenbosch University Tygerberg Hospital24
进行中（未招募）
1 期
Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV)in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive. Revised Protocol 02, incorporating Protocol Amendment 01 (v1.0, date 18-Apr-2008), and Protocol Amendment 04 (v1.0, date 05-Dec-2008).Chronic Hepatitis B Virus (HBV) InfectionMedDRA version: 8.1Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)EUCTR2005-005816-26-BEBristol-Myers Squibb International Corporation64